A novel, disruptive vaccination technology

References

• Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011; 11:865 - 72; PMID: 22051890
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465 - 8; http://dx.doi.org/10.1126/science.1690918; PMID: 1690918
   PubMed Web of Science ®Google Scholar
• Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993; 23:1719 - 22; http://dx.doi.org/10.1002/eji.1830230749; PMID: 8325342
   PubMed Web of Science ®Google Scholar
• Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995; 55:1397 - 400; PMID: 7882341
   PubMed Web of Science ®Google Scholar
• Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30:1 - 7; http://dx.doi.org/10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#; PMID: 10602021
   PubMed Web of Science ®Google Scholar
• Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004; 4:1285 - 94; http://dx.doi.org/10.1517/14712598.4.8.1285; PMID: 15268662
   PubMed Web of Science ®Google Scholar
• Pascolo S. Vaccination with messenger RNA. Methods Mol Med 2006; 127:23 - 40; PMID: 16988444
   PubMedGoogle Scholar
• Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 2012; 30:4414 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.04.060; PMID: 22546329
   PubMed Web of Science ®Google Scholar
• Gust TC, Zenke M. RNA transfer and its use in dendritic cell-based immunotherapy. Expert Opin Biol Ther 2005; 5:173 - 81; http://dx.doi.org/10.1517/14712598.5.2.173; PMID: 15757379
   PubMed Web of Science ®Google Scholar
• Probst J, Fotin-Mleczek M, Schlake T, Thess A, Kramps T, Kallen KJ. Messenger RNA vaccines. Springer Verlag Wien, 2012.
   Google Scholar
• Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol 2012; 9:1319 - 30; http://dx.doi.org/10.4161/rna.22269; PMID: 23064118
   PubMed Web of Science ®Google Scholar
• Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61:2418 - 24; http://dx.doi.org/10.1007/s00018-004-4255-0; PMID: 15378210
   PubMed Web of Science ®Google Scholar
• Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004; 34:537 - 47; http://dx.doi.org/10.1002/eji.200324198; PMID: 14768059
   PubMed Web of Science ®Google Scholar
• Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005; 35:1557 - 66; http://dx.doi.org/10.1002/eji.200425656; PMID: 15832293
   PubMed Web of Science ®Google Scholar
• Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006; 36:2807 - 16; http://dx.doi.org/10.1002/eji.200635910; PMID: 17013976
   PubMed Web of Science ®Google Scholar
• Banerjee AK. 5′-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev 1980; 44:175 - 205; PMID: 6247631
   PubMedGoogle Scholar
• Wickens M. How the messenger got its tail: addition of poly(A) in the nucleus. Trends Biochem Sci 1990; 15:277 - 81; http://dx.doi.org/10.1016/0968-0004(90)90054-F; PMID: 1974368
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010; 70:9031 - 40; http://dx.doi.org/10.1158/0008-5472.CAN-10-0699; PMID: 21045153
   PubMed Web of Science ®Google Scholar
• Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci O, Sahin U. Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biol 2011; 8:35 - 43; http://dx.doi.org/10.4161/rna.8.1.13767; PMID: 21289486
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011; 34:1 - 15; http://dx.doi.org/10.1097/CJI.0b013e3181f7dbe8; PMID: 21150709
   PubMed Web of Science ®Google Scholar
• Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WP, et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 2011; 8:627 - 36; http://dx.doi.org/10.4161/rna.8.4.15394; PMID: 21654214
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263 - 70; http://dx.doi.org/10.1038/nm1191; PMID: 15723075
   PubMed Web of Science ®Google Scholar
• Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Türeci O, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011; 18:702 - 8; http://dx.doi.org/10.1038/gt.2011.17; PMID: 21368901
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med 2012; 14:428 - 39; http://dx.doi.org/10.1002/jgm.2605; PMID: 22262664
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012; 30:1210 - 6; http://dx.doi.org/10.1038/nbt.2436; PMID: 23159882
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13 - 7; http://dx.doi.org/10.1056/NEJM198307073090103; PMID: 6602294
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745 - 9; http://dx.doi.org/10.1126/science.8456302; PMID: 8456302
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007; 18:529 - 36; http://dx.doi.org/10.1016/j.copbio.2007.11.002; PMID: 18083548
   PubMed Web of Science ®Google Scholar
• Chaloupka I, Schuler A, Marschall M, Meier-Ewert H. Comparative analysis of six European influenza vaccines. Eur J Clin Microbiol Infect Dis 1996; 15:121 - 7; http://dx.doi.org/10.1007/BF01591484; PMID: 8801083
   PubMed Web of Science ®Google Scholar
• Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012; 72:1661 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-11-2957; PMID: 22337996
   PubMed Web of Science ®Google Scholar
• Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res 2011; 71:6132 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-11-0291; PMID: 21816907
   PubMed Web of Science ®Google Scholar
• Sebastian M, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, et al. Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial. J Clin Oncol 2011; 29:2584
   Google Scholar
• Sebastian M, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, et al. Messenger RNA vaccination and B-cell responses in NSCLC patients. J Clin Oncol 2012; 30:2573; PMID: 22565006
   PubMed Web of Science ®Google Scholar
• Kübler H, Maurer T, Stenzl A, Feyerabend S, Steiner U, Schostak M, et al. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. J Clin Oncol 2011; 29:4535
   Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254 - 61; http://dx.doi.org/10.1038/nm.2883; PMID: 22842478
   PubMed Web of Science ®Google Scholar